Skip to content

Comparison of DNA Ploidy and Conventional Cytology

A Prospective Comparison of Digital Image Analysis and Routine Cytology for the Identification of Pancreatic Neoplasia in Patient Undergoing EUS-FNA

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02921100
Enrollment
150
Registered
2016-09-30
Start date
2015-01-31
Completion date
Unknown
Last updated
2016-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biopsy, Fine-Needle

Brief summary

150 patients who had suspected pancreatic malignancy were planed to be enrolled in this study. Equal cytological samples of each patient undergoing EUS-FNA were examined by digital image analysis and conventional cytology respectively. The investigators aim to compare the efficacy of DIA and conventional cytology in diagnosing pancreatic cancer. Further more, the investigators also collected the blood sample of each enrolled patient for advanced study.

Detailed description

The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells. The specimens were examined by two experienced cytopathologists. Any disagreement on specimens would refer to a third cytopathologist to provide a final consensus. The former two diagnosis were determined to be positive, and the latter two to be negative. DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry. Computer analysis of the pixels produces a digital image of the nucleus and other cellular constituents. Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy. ThinPrep specimens were prepared as previously described.Per specimen, the DNA content of at least 500 cells was selected for quantification using an image analyzer (Landing Medical High-tech, Wuhan, Hubei, China) and the mean integrated optical density lymphocytes served as an internal standard control. All other histograms suggesting the presence of (1) any cells with DNA\>5c; (2) diploidy cells with a very high proliferation rate where 10% or more of the total cells were found in the proliferation fraction; and (3) a population of aneuploidy stem cells, were called positive for malignancy. Images of cells reporting a DNA amount greater than 5c were examined microscopically by a cytotechnologist to exclude any artifacts such as dust, air bubbles, overlapping cells, etc. from the \>5c cell galleries. All the final diagnosis are to be confirmed by histopathology or a long term follow up.

Interventions

DEVICEEUS-guided fine needle
PROCEDUREcytology

The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.

PROCEDUREDNA ploidy

DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy

PROCEDUREEUS-FNA

All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. who had known or suspected pancreatic malignancy and 2. in whom the endosonographer deemed the target lesion safe and feasible to allow the necessary study passes.

Exclusion criteria

1. not willing to sign informed consent, 2. cells obtained from FNA for DNA ploidy test less than 200, and/or 3. patients do not cooperate with follow-up.

Design outcomes

Primary

MeasureTime frame
Proportion of participants with accurate diagnosis by conventional cytology versus by DNA ploidy test12 months

Secondary

MeasureTime frame
sensitivity of conventional cytology Versus DNA ploidy test in the diagnosis of pancreatic malignancy12 months
specificity of conventional cytology Versus DNA ploidy test in the diagnosis of pancreatic malignancy12 months
positive predictive value of conventional cytology Versus DNA ploidy test in the diagnosis of pancreatic malignancy12 months
negative predictive value of conventional cytology Versus DNA ploidy test in the diagnosis of pancreatic malignancy12 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026